Hemolink delivers significant oxygen, says study:
This article was originally published in Clinica
Executive Summary
The oxygen-carrying characteristics of Hemosol's blood substitute, Hemolink, are similar to those of fresh blood, according to the results of an in vitro study. The speed by which Hemolink retrieved and delivered oxygen was fast and appeared to coincide with the normal blood process, said Canadian researchers, who presented the findings at last week's American Society of Hematology meeting in Orlando, Florida. "This study is further confirmation of Hemolink's ability to retrieve oxygen in the lungs and immediately, efficiently and safely deliver it to the body's organs to treat acute anaemia," added Toronto-based Hemosol.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.